Literature DB >> 21319202

Nuclear receptors in liver disease.

Martin Wagner1, Gernot Zollner, Michael Trauner.   

Abstract

Nuclear receptors are ligand-activated transcriptional regulators of several key aspects of hepatic physiology and pathophysiology. As such, nuclear receptors control a large variety of metabolic processes including hepatic lipid metabolism, drug disposition, bile acid homeostasis, as well as liver regeneration, inflammation, fibrosis, cell differentiation, and tumor formation. Derangements of nuclear receptor regulation and genetic variants may contribute to the pathogenesis and progression of liver diseases. This places nuclear receptors into the frontline for novel therapeutic approaches for a broad range of hepatic disorders and diseases including cholestatic and fatty liver disease, drug hepatotoxicity, viral hepatitis, liver fibrosis, and cancer.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21319202     DOI: 10.1002/hep.24148

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  92 in total

1.  Effects of statins on cholestasis: good, bad or indifferent?

Authors:  Rahul Kuver
Journal:  J Gastroenterol Hepatol       Date:  2011-10       Impact factor: 4.029

2.  The role of nuclear receptors in the kidney in obesity and metabolic syndrome.

Authors:  Claudia Tovar-Palacio; Nimbe Torres; Andrea Diaz-Villaseñor; Armando R Tovar
Journal:  Genes Nutr       Date:  2012-04-25       Impact factor: 5.523

3.  Protective Effects of Alisol B 23-Acetate Via Farnesoid X Receptor-Mediated Regulation of Transporters and Enzymes in Estrogen-Induced Cholestatic Liver Injury in Mice.

Authors:  Qiang Meng; Xinli Chen; Changyuan Wang; Qi Liu; Huijun Sun; Pengyuan Sun; Xiaokui Huo; Zhihao Liu; Jihong Yao; Kexin Liu
Journal:  Pharm Res       Date:  2015-06-04       Impact factor: 4.200

4.  Impaired bile acid handling and aggravated liver injury in mice expressing a hepatocyte-specific RXRα variant lacking the DNA-binding domain.

Authors:  Astrid Kosters; Julio C Felix; Moreshwar S Desai; Saul J Karpen
Journal:  J Hepatol       Date:  2013-10-10       Impact factor: 25.083

Review 5.  FXR Agonists: From Bench to Bedside, a Guide for Clinicians.

Authors:  Ahmad Samer Alawad; Cynthia Levy
Journal:  Dig Dis Sci       Date:  2016-10-12       Impact factor: 3.199

6.  Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population.

Authors:  Min-Sun Kwak; Donghee Kim; Goh Eun Chung; Won Kim; Yoon Jun Kim; Jung-Hwan Yoon
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 7.  Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease.

Authors:  Fernando Ezquer; Flavia Bruna; Sebastián Calligaris; Paulette Conget; Marcelo Ezquer
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 8.  Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination?

Authors:  Moon-Sun Kim; Madeleine Ong; Xianqin Qu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

9.  A novel role of astrocyte elevated gene-1 (AEG-1) in regulating nonalcoholic steatohepatitis (NASH).

Authors:  Jyoti Srivastava; Chadia L Robertson; Kareem Ebeid; Mikhail Dozmorov; Devaraja Rajasekaran; Rachel Mendoza; Ayesha Siddiq; Maaged A Akiel; Nidhi Jariwala; Xue-Ning Shen; Jolene J Windle; Mark A Subler; Nitai D Mukhopadhyay; Shah Giashuddin; Shobha Ghosh; Zhao Lai; Yidong Chen; Paul B Fisher; Aliasger K Salem; Arun J Sanyal; Devanand Sarkar
Journal:  Hepatology       Date:  2017-06-30       Impact factor: 17.425

Review 10.  Med1 subunit of the mediator complex in nuclear receptor-regulated energy metabolism, liver regeneration, and hepatocarcinogenesis.

Authors:  Yuzhi Jia; Navin Viswakarma; Janardan K Reddy
Journal:  Gene Expr       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.